13‐valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6‐17 years of age with sickle cell disease previously vaccinated with 23‐valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 8, 2015-08 ,pp. : 1427-1436

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden

By Bergman Annika   Hjelmgren Jonas   Ortqvist Åke   Wisløff Torbjørn   Sønbø Kristiansen Ivar   Diaz Hogberg Liselotte   M-S Persson Kristina   Persson Ulf  

Scandinavian Journal of Infectious Diseases, Vol. 40, Iss. 9, 2008-01 ,pp. : 721-729

Informa Healthcare

Access to resources Recommend Favorite

Serotype replacement of Streptococcus pneumoniae due to seven‐valent pneumococcal conjugate vaccine in Japan

By  

PEDIATRICS INTERNATIONAL, Vol. 60, Iss. 1, 2018-01 ,pp. : 52-56

John Wiley & Sons Inc

Access to resources Recommend Favorite

Economic impact of pneumococcal conjugate vaccination in Brazil, Chile, and Uruguay

By Constenla Dagna O.  

Revista Panamericana de Salud Pública/Pan American Journal of Public Health, Vol. 24, Iss. 2, 2008-08 ,pp. : 101-112

Pan American Health Organization (PAHO)

Access to resources Recommend Favorite

10‐valent pneumococcal non‐typeable Haemophilus influenzae protein‐D conjugate vaccine (PHiD‐CV) induces memory B cell responses in healthy Kenyan toddlers

By  

CLINICAL & EXPERIMENTAL IMMUNOLOGY, Vol. 181, Iss. 2, 2015-08 ,pp. : 297-305

John Wiley & Sons Inc

Access to resources Recommend Favorite